The UK and US have concluded a major bilateral deal that will preserve no levies on British pharmaceutical exports entering the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has agreed to increase funding on pharmaceuticals through the NHS. This pledge secures that duties on these key products will be held at nothing for a timeframe of 36 months.
This development comes after recent threats to significantly raise import taxes on patented drug products, with potential rates discussed up to 100%.
"This agreement between the Britain strengthens the international landscape for innovative medicines and establishes long-overdue balance to American-British medicine commerce," a statement noted.
Commercial Impact
Medicines constitute one of the UK's largest export categories to the United States, which is clearly the biggest buyer for leading companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period prior to September, the UK sold medicines totaling billions to the US. This amount represented a significant portion of total UK exports in that span.
"This agreement secures work, increases capital expenditure and paves the way for the UK to emerge as a global hub for medical research," a government official commented.
Specific UK Commitments
The deal includes several specific commitments from the UK:
- Price Threshold Increase: The UK will lift the affordability limit at which it considers new treatments to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a target to raise total health service expenditure on treatments from 0.3% of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The percentage drug companies must pay back to the NHS to stay within budget will be restricted at 15%. Previously, rebates topped twenty percent.
Industry Background
The deal takes place against a ongoing dispute between the drug companies and the British authorities over medicine costs and regulatory access.
This friction were intensified by assertions that US customers were charged several times more for the same drugs than consumers in the other developed nations.
Recently, several major drug company projects in the UK have been delayed or abandoned, while major expansions have been directed toward projects in the United States.
One official acknowledged that the NHS had to invest a greater share on drugs, noting that its expenditure on drugs had decreased as a proportion of its resources over the past decade.
